Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Pancreatic cancer is almost invariably associated with mutations in the KRAS gene, most commonly KRASG12D, that result in a dominant-active form of the KRAS GTPase. However, how KRAS mutations promote pancreatic carcinogenesis is not fully understood, and whether oncogenic KRAS is required for the maintenance of pancreatic cancer has not been established. To address these questions, we generated two mouse models of pancreatic tumorigenesis: mice transgenic for inducible KrasG12D, which allows for inducible, pancreas-specific, and reversible expression of the oncogenic KrasG12D, with or without inactivation of one allele of the tumor suppressor gene p53. Here, we report that, early in tumorigenesis, induction of oncogenic KrasG12D reversibly altered normal epithelial differentiation following tissue damage, leading to precancerous lesions. Inactivation of KrasG12D in established precursor lesions and during progression to cancer led to regression of the lesions, indicating that KrasG12D was required for tumor cell survival. Strikingly, during all stages of carcinogenesis, KrasG12D upregulated Hedgehog signaling, inflammatory pathways, and several pathways known to mediate paracrine interactions between epithelial cells and their surrounding microenvironment, thus promoting formation and maintenance of the fibroinflammatory stroma that plays a pivotal role in pancreatic cancer. Our data establish that epithelial KrasG12D influences multiple cell types to drive pancreatic tumorigenesis and is essential for tumor maintenance. They also strongly support the notion that inhibiting KrasG12D, or its downstream effectors, could provide a new approach for the treatment of pancreatic cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prior studies have demonstrated that genetic ablation of KRAS expression leads to cell cycle arrest and death in cell lines and potent tumor regressions in animal models of PDAC (5–7).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [7]
In the citing paper
“Extinguishing the expression of mutant Kras in the pancreas led to rapid tumor regression, thus demonstrating a critical role of Kras in tumor maintenance (73, 78).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [78]
In the citing paper
“Withdrawal of oncogenic Kras resulted in regression of invasive neoplasia, including regression of metastatic disease63–65.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [63]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Research works printed but not linked: 2
- Klimstra, 1994, Am J Pathol., 145, 1547
- Caldwell, Oncogene.
Cited by
Items 601–700 of 769
The IGF-I/IGF-IR Signaling System and Pancreatic Cancer
Kopantzev, E. P., Гранкина, Е. В., Kopantseva, M. R., & Sverdlov, E. D. (2017) · Molecular Genetics Microbiology and Virology · doi:10.3103/s0891416817030041 · Cited by 3
Mechanisms of Hippo pathway in the pancreatic cancer
Xie, R., & Chen, R. (2020) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000041 · Cited by 4
Quadruplex nucleic acids in KRAS targeted-cancer therapy
Xodo, L. E. (2020) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2020.04.004 · Cited by 3
Woolley, T. E., Hill, W., & Hogan, C. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111024 · Cited by 3
“However, mutations in the oncogene KRas (KRasG12D): drive the most common form of pancreatic ductal adenocarcinoma (PDAC); are detected in > 90 % of human tumours (Kleeff et al. (2016)); and are required at all stages of PDAC (Collins et al. (2012)).”
Yu, J., Li, H., Wang, J., Chen, X., Lu, L., Wei, Y., Wang, Y., & Mo, S. (2023) · Journal of Cancer · doi:10.7150/jca.79905 · Cited by 4
“Aberrant activation of extracellular regulated protein kinase (ERK) represents the remarkable oncogenic event in PDAC [16, 17]; however, the linkage between ERK and EYA4, particularly whether and how ERK orchestrates EYA4 in pathogenesis of PDAC remains undefined.”
The Role of Dicer Phosphorylation in Gemcitabine Resistance of Pancreatic Cancer
Chiu, C., Lin, H.-R., Su, Y., Chen, H., Hung, S., & Huang, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111797 · Cited by 3
Wu, S., Wu, X., Zhou, G., Deng, L., Pang, P., Tang, H., Xu, H., Shi, Y., & Chen, X. (2018) · Phytochemistry Letters · doi:10.1016/j.phytol.2018.07.019 · Cited by 3
Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics
Layeghi‐Ghalehsoukhteh, S., Choudhuri, S. P., Ocal, O., Zolghadri, Y., Pashkov, V., Niederstrasser, H., Posner, B. A., Kantheti, H. S., Azevedo‐Pouly, A. C. P., Huang, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77373-8 · Cited by 3
Unlocking PDAC initiation with AP-1
LaFave, L. M., & Buenrostro, J. D. (2021) · Nature Cancer · doi:10.1038/s43018-020-00158-5 · Cited by 3
Emerging therapies for pancreatic ductal carcinoma
Falcone, R., Davis, P. J., Stain, S. C., & Mousa, S. A. (2016) · Journal of Solid Tumors · doi:10.5430/jst.v6n1p65 · Cited by 3
“[9] A separate study showed that mice with inducible K-Ras mutations initiated carcinogenesis by inhibiting the repair of the pancreas.[10] This same study showed that inactivation of K-Ras led to tumor regression.”
BackgroundJia, X., Sun, B., Tu, Q., Qi, H., Li, L., Liu, X., Yan, L., Dai, H., Kong, Q., Tang, C., et al. (2021) · Pancreatology · doi:10.1016/j.pan.2021.01.004 · Cited by 3
Synergistic effect of antagonists to KRas4B/PDE6 molecular complex in pancreatic cancer
Briseño-Díaz, P., Schnoor, M., Bello, M., Correa‐Basurto, J., Rojo‐Domínguez, A., Arregui, L., Vega, L., Núñez-González, E., Palau-Hernández, L. A., Parra-Torres, C. G., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202302019 · Cited by 4
“Approximately 99% of PDAC patients have activating mutations in the KRAS oncogene, providing PDAC cells with antiapoptotic and chemoresistance properties (Collins et al, 2012).”
BackgroundWilliams, T. M., Estrada, A., Chatterjee, M., Yang, L., Morgan, M. A., & Robinson, C. A. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.07.975 · Cited by 4
Oncogenic KRAS engages an RSK1/NF1 complex in pancreatic cancerPreprint
Cheng, D. K., Oni, T. E., Park, Y., Thalappillil, J. S., Ting, H.-C., Alagesan, B., Prasad, N. V., Rivera, K. D., Pappin, D., Aelst, L. V., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.14.295394 · Cited by 3
“Additionally, independent studies have shown that the maintenance of murine PDAC cells require KRAS[12-14].”
BackgroundDatta, J., Dai, X., Bianchi, A., Silva, I. D. C., Mehra, S., Garrido, V. T., Lamichhane, P., Singh, S. P., Zhou, Z., Dosch, A. R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.07.434236 · Cited by 3
“Resistance to ICI is a hallmark of PDAC (5,6), defined by T-cell exclusion and tissue-level immune tolerance driven by KRAS-mediated tumor-intrinsic programs (1,8) as well as interwoven suppressive cellular networks comprising innate immune populations and tumor-promoting cancer-associated fibroblasts (CAF) (7).”
BackgroundDagli, M. L., Chaible, L. M., & Steiger, K. (2021) · Wiley eBooks · doi:10.1002/9781119624608.ch15 · Cited by 4
Carpenter, E. S., Elhossiny, A. M., Kadiyala, P., Li, J., McGue, J. J., Griffith, B. D., Zhang, Y., Edwards, J., Nelson, S., Lima, F., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.13.523300 · Cited by 3
“While mouse models have been instrumental to understand the early stages of pancreas carcinogenesis and to study the healthy organ(37-40), they are a poor substitute for human samples.”
BackgroundSelf-citationMahadevan, K. K., Dyevoich, A. M., Chen, Y., Li, B., Sugimoto, H., Sockwell, A. M., McAndrews, K. M., Wang, H., Shalapour, S., Watowich, S. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.05.531191 · Cited by 3
Bortoletto, A. S., Yang, Z., Cardenas, M. G., Wang, M.-T., McCormick, F. P., & Parchem, R. J. (2023) · Research Square · doi:10.21203/rs.3.rs-3064215/v1 · Cited by 3
Monga, J., Ghosh, R., Guddeti, R. K., Chitale, D. A., Khan, G. N., & Ghosh, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1387535 · Cited by 2
Wilms Tumor 1–Expressing Stromal Cells Promote Pancreatic Cancer Progression
Bischoff, A. C., Brown, K. L., Opsahl, E. L. L., Watkoske, H. R., Espinoza, C. E., Okoye, J. O., Olivei, A. C., Green, L. M., Rai, R., The, S., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1014 · Cited by 2
“Pancreatic cancer is characterized by the establishment of a fibroinflammatory microenvironment comprised largely of CAFs (3–5).”
Self-citationLY6D identifies persistent stem-like cells driving pancreatic tumourigenesis
Shi, J., Wang, X., Tang, Y., Meng, S., Zhang, Z., Lu, P., Xu, J., Yu, F., Wang, X., Wang, Z., et al. (2026) · Gut · doi:10.1136/gutjnl-2025-336460 · Cited by 3
“Pancreatic tumourigenesis begins with remarkable cellular heterogeneity, 39 40 as oncogenic KRAS activation on tissue injury induces multiple distinct premalignant cell states—including tuft-like, neuroendocrine, progenitor-like and gastric-like.”
Dahiya, S., Arbujas, J. R., Hajihassani, A., Amini, S., Wageley, M., Gurbuz, K., Ma, Z., Copeland, C., Saleh, M. W., Gittes, G. K., et al. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2026.101743 · Cited by 2
“15,16 Given the involvement of ADM in acinar regeneration and its role as a precursor to PanINs, pancreatic neoplasia has been popularly defined as a regenerative process highjacked by oncogenic KRAS.”
Lipid signaling networks in pancreatic cancer progression and therapeutic perspectives
Costamagna, A., Milan, G., Santis, M. C. D., Carrer, A., & Martini, M. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2026.03.004 · Cited by 6
“KRAS-driven metabolic rewi ring Oncogenic KRAS elicits and maintains pancreatic carcinogenesis, while extinction of KRAS signaling induces regression of established tumors in mice [72,73].”
Alterations in genes involved in glycolysis and hypoxia affect the prognosis of pancreatic cancer
Zou, J., Zhu, Q., Sun, Y., Zhang, W., & Huang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34104 · Cited by 2
“Besides, when we studied SNP, we found that KRAS mutations were more frequent in the hypoxic subtype, and KRAS mutations are one of the strongest oncogenic drivers in all cancers [37].”
BackgroundJara, C. P., Al-Gahmi, A.-M., Lazenby, A. J., Hollingsworth, M. A., & Carlson, M. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-87178-2 · Cited by 2
Ray, P., Shukla, S., Zhang, Y., Donahue, K. L., Nancarrow, D. J., Kasturirangan, S., Shankar, S., Cuneo, K. C., Thomas, D. G., Gadgeel, S. M., et al. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0701 · Cited by 5
Self-citationRoad Map to Defeat Pancreatic Cancer
Ferguson, L. P., & Tuveson, D. A. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060624-044323 · Cited by 3
STAT3 sustains tumorigenicity following mutant KRAS ablation
D’Amico, S., Kirillov, V., Liu, J., Qiu, Z., Lei, X., Qin, H., Sheridan, B. S., & Reich, N. C. (2025) · EMBO Reports · doi:10.1038/s44319-025-00563-w · Cited by 2
The Role of CXCR2 in Pancreatic Cancer Development and Progression
Purohit, A. (2015) · DigitalCommons@UNMC · Cited by 3
Animal Modeling of Pancreatitis-to-Cancer Progression
Martinelli, P., & Real, F. X. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_66 · Cited by 2
Immuno-Oncology in Pancreatic Cancer
Jamieson, N. B., & Steele, C. W. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_20 · Cited by 2
Bailey, J. M., Hendley, A. M., & Maitra, A. (2015) · Pancreas · doi:10.1097/mpa.0000000000000374 · Cited by 2
“Other critical events during PanIN formation include loss of expression of Nr5a2 and digestive proenzymes.(5,8) The pronounced molecular plasticity of pancreatic acinar cells has stunning implications for the plasticity of pancreatic cancer cells.”
BackgroundCombined SHP2 and ERK inhibition for the treatment of KRAS-driven Pancreatic Ductal AdenocarcinomaPreprint
Ciecielski, K. J., Mulero‐Sánchez, A., Berninger, A., Cañas, L. R., Bosma, A. R., Görgülü, K., Wu, N., Diakopoulos, K. N., Kaya-Aksoy, E., Ruess, D. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.14.472574 · Cited by 2
“pancreatic tumorigenic process (8), and that pancreatic adenocarcinomas retain a high dependency on RAS signaling (9, 10), thus making KRAS the ideal therapeutic target for pancreatic cancer.”
BackgroundGlucose-6-phosphate dehydrogenase deficiency accelerates pancreatic acinar-to-ductal metaplasiaPreprint
Radyk, M. D., Nelson, B. S., Halbrook, C. J., Wood, A., Lavoie, B. L., Salvatore, L., Corfas, G., Colacino, J. A., Shah, Y. M., Crawford, H. C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.06.565895 · Cited by 2
Drug-Induced p53 Activation Limits Pancreatic Cancer InitiationPreprint
Twardowski, J. J., Heist, T. I., Soares, Z. G., Berry, E. S., Ruffolo, L. I., Pröschel, C., & Mello, S. S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.29.595146 · Cited by 4
“The essential role of Kras mutations in the initiation and maintenance of PDAC has been established by several studies using genetically engineered mouse models 3-5 .”
BackgroundDiagnostic and Prognostic Markers for Pancreatitis and Pancreatic Ductal Adenocarcinoma
Kantheti, H. S., Hale, M. A., Choudhuri, S. P., Huang, H., Wang, X., Zolghadri, Y., Innamorati, G., Manikonda, S. P. R., Reddy, N. R., Reddy, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126619 · Cited by 1
“Oncogenic Kras mutations are acquired early in PDA progression, but alone, these mutations only destabilize acinar and ductal cell identity [20].”
BackgroundInactivation of HIPK2 attenuates KRASG12D activity and prevents pancreatic tumorigenesis
Sozzi, S., Manni, I., Ercolani, C., Diodoro, M. G., Bartolazzi, A., Spallotta, F., Piaggio, G., Monteonofrio, L., Soddu, S., Rinaldo, C., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03189-3 · Cited by 2
“Of relevance, this reduced oncogenic KRAS activity resulted in pancreatic phenotypes that mirror the observation made by direct mutant KRAS silencing through doxy-cycline inducible and reversible system [35] and, more recently, by mutant-KRAS-specific pharmacological inactivation [45].”
BackgroundResultInfluentialPRRX1 Has Functional Roles in Pancreatic Acinar to Ductal Metaplasia and Carcinogenesis
Nishiwaki, N., Sugiura, K., Suzuki, K., Li, A. L., Contreras, C. T., Efe, G., Shin, A. E., Sadeghian, D., Zhao, J., Maitra, A., et al. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101442 · Cited by 1
Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors
Anastasio, G., Felaco, M., Lamolinara, A., Pizzo, F., Cacciagrano, E., Mottini, C., Mutarelli, M., Modugno, F. D., Iezzi, M., & Cardone, L. (2025) · iScience · doi:10.1016/j.isci.2025.111842 · Cited by 1
Yan, B., Fritsche, A., Haußner, E., Inamdar, T. V., Laumen, H., Boettcher, M., Gericke, M. T., Michl, P., & Rosendahl, J. (2025) · Cancers · doi:10.3390/cancers17101676 · Cited by 1
“Collins et al. generated triple transgenic R26-rtTa-IRES-EGFP; TetO-Kras G12D ; p48 -Cre mice [55].”
Biomarkers in cystic lesions of the pancreas: Controversies and advances
Liu, L., Fan, Z., & Zhan, H. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189392 · Cited by 1
Dong, B., Zhang, Y., Kang, T., Wang, F., & Su, G. (2025) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2025.2545968 · Cited by 2
Self-citationZhou, D., Zhong, C., Yang, Q., Cui, B., & Wang, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1671956 · Cited by 1
KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor Regression
Qiao, Y., Yee, M. F., Parikh, C. N., Ma, B., Cao, Y., Shih, Y., Wu, J. Q., Ruscetti, M. A., Liang, S., & Xue, W. (2025) · Advanced Science · doi:10.1002/advs.202511312 · Cited by 3
Pancreatic Cancer—Advances in the Last 50 Years
Barreto, S. G., Maitra, A., O'Reilly, E. M., Sahani, D., Zheng, R., & Yeo, C. J. (2026) · World Journal of Surgery · doi:10.1002/wjs.70309 · Cited by 2
Advancing precision medicine in pancreatic cancer using novel biomarkers and clinical targets
Murthy, D., Seyhan, A. A., den Hollander, P., Lu, S., Kuburich, N. A., Gould, C., Karam, A., Sun, K., Schupp, P. G., Safran, H., et al. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101476 · Cited by 3
Artificial intelligence: Catalyzing a new era in pancreatic cancer cure
Wang, J., Luo, W., Zhang, M., Wang, Y., Ye, L., Qiu, J. U. N. T. A. O., Liu, Y., Weng, G., Liu, T., Cao, Z., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218558 · Cited by 1
EPHA2/CD44-directed trafficking enhances endosomal leakiness and antisense therapy delivery
Marco, S., Walsh, P. J., Revenko, A. S., Schmidt, T., Thomason, P. A., McGarry, L., MacLeod, A. R., Ansel, S., Tataran, D., Bushell, M., et al. (2026) · The Journal of Cell Biology · doi:10.1083/jcb.202507217 · Cited by 2
“In pancreatic cancer, KRAS mutation is a key driver of tumor initiation, and mutant Kras deletion induces regression in pre-clinical models (Collins et al., 2012; Ying et al., 2012).”
Li, Q., Hoffman, M. T., Chun, J.-H., Parent, B. D., Hambitzer, F., Peprah, F., Kureshi, C. T. S., Lim, B. S., Chang, E., Walsh, M. J., et al. (2026) · Cell · doi:10.1016/j.cell.2026.08.045 · Cited by 1
Mouse Models of Pancreatic Ductal Adenocarcinoma
Bednar, F., & di Magliano, M. P. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6549-2_7 · Cited by 1
“Kras OFF Kras under the control of a Tet operator; PanIN development is accelerated by induction of pancreatitis; PDA formation required loss of p53 (Collins et al., 2012; Ying et al., 2012)”
BackgroundSelf-citationTaucher, V., & Haybaeck, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-53661-3_5 · Cited by 1
Mutant K-Ras-Mediated Oxidative Stress in Pancreatic Cancer
Thomas, D., Sagar, S., Caffrey, T., & Radhakrishnan, P. (2022) · Springer eBooks · doi:10.1007/978-981-15-9411-3_94 · Cited by 1
Mouse Models of Pancreatic Exocrine Cancer
Pérez-Mancera, P. A. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_77 · Cited by 1
Risk Factors for Pancreatic Cancer: Underlying Mechanisms and Potential Targets
(2015) · Frontiers research topics · doi:10.3389/978-2-88919-468-1 · Cited by 1
Application of artificial intelligence and machine learning in pancreatic cancer immunotherapy
Ahmed, N. S., Gorrie, R. P., Meguid, T., Nelson, C., Basha, R. M., & Siraj, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23523-8.00022-5 · Cited by 1
Lung cancer samples preserved in liquid medium: One step beyond cytology
Mariano, V. S., Leal, L. F., Pastrez, P. R. A., Silva, E. M., Reis, R. M., & Longatto‐Filho, A. (2017) · Diagnostic Cytopathology · doi:10.1002/dc.23743 · Cited by 1
Animal Modeling of Pancreatitis-to-Cancer Progression
Martinelli, P., & Real, F. X. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_66-1 · Cited by 1
Drug Discovery from Natural Products for Pancreatic Cancer
Ramos, M. C., Genilloud, O., Reyes, F., & Vicente, F. (2018) · InTech eBooks · doi:10.5772/intechopen.76399 · Cited by 1
“Pathways with relevant novel targets are: K-ras (Raf [32], MAPK, Erk, PI3Ks, PDK-1 [33]; p53 [34]; growth factor (EGF, EGFR [35], FGF, FGFR [36], VEGF [37], IGF [38]) and the pathway of epithelial to mesenchymal transition (Wnt/β-catenin [39], TNFα [40], Notch [41], Snail-1, Slug, E-cadherin [42]).”
BackgroundMukundan, S., Sharma, K. S., Honselmann, K. C., Singleton, A., Liss, A. S., & Parekkadan, B. (2018) · Technology in Cancer Research & Treatment · doi:10.1177/1533033818803632 · Cited by 1
Emerging Technologies for the Diagnosis and Treatment of Pancreatic Cancer
Swierczewska, M., Козлов, С. В., & Adiseshaiah, P. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00022-3 · Cited by 1
Nishizawa, N., Kumamoto, Y., Katoh, H., Ushiku, H., Yokoi, K., Tanaka, T., Ishii, S., Igarashi, K., Tajima, H., Kaizu, T., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9839 · Cited by 1
“An inducible KrasG12D model elucidated that a precursor lesion with an activated K-ras signal transforms to carcinoma but a precursor lesion with an inactivated K-ras signal undergoes apoptosis (36).”
BackgroundEvolving trends in pancreatic cancer therapeutic development
Bijou, I., & Wang, J. (2019) · Annals of Pancreatic Cancer · doi:10.21037/apc.2019.09.01 · Cited by 2
“If mutated KRAS is switched to unmutated KRAS using genetic approaches, the desmoplasia proliferation rate slows down after a few days (97).”
BackgroundPotential of PAR-4 as a Therapeutic Target for Pancreatic Cancer
Uddin, M. H., Azmi, A. S., & Mohammad, R. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-80558-6_10 · Cited by 3
Experimental Model for Pancreatic Cancer and Its Therapeutic Implications in Clinical Research
Jayaraman, S., Ponnusamy, B., Rajagopal, P., Kumar, S. G., & Chandrasekar, K. (2023) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-3824-5_39 · Cited by 1
Zheng, Z., Chen, Z., Lin, Y., & Wei, J. (2023) · AIP Advances · doi:10.1063/5.0162189 · Cited by 1
Schneider, G., & Saur, D. (2013) · Oncotarget · doi:10.18632/oncotarget.1322 · Cited by 1
Multi-dimensional analyses identify genes of high priority for pancreatic cancer researchPreprint
Nwosu, Z. C., Giza, H., Nassif, M., Charlestin, V., Menjivar, R. E., Kim, D., Kemp, S. B., Steele, N. G., Hu, J., Hu, B., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.28.446056 · Cited by 1
Ductal Adenocarcinoma and Variants
Karamitopoulou-Diamantis, E. (2022) · Encyclopedia of pathology · doi:10.1007/978-3-030-62416-3_5538 · Cited by 2
Marco, S., Walsh, P. J., Revenko, A. S., Thomason, P. A., McGarry, L., MacLeod, A. R., Ansel, S., Tataran, D., Bushell, M., Braconi, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.05.635637 · Cited by 1
Aspartate Transaminases Are Dispensable for Pancreatic Development and Pancreatic Cancer ProgressionPreprint
Ugras, J., Nelson, N. S., Kerk, S. A., Sutton, D., Lin, L., Sajjakulnukit, P., Dombrowski, T., Davidson, G., Lavoie, B. L., Awad, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.17.694916 · Cited by 1
Self-citationThe Biology of K-Ras Signaling Pathways in Pancreatic Cancer
Court, H., Philips, M. R., & Bar‐Sagi, D. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6549-2_5
Hayes, T. K., Stratford, J. K., Wang‐Gillam, A., & Der, C. J. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1806-1_7 · Cited by 1
Neuroplastic changes in a mouse model of pancreatic ductal adenocarcinoma
Stopczynski, R. E. (2013) · D-Scholarship@Pitt (University of Pittsburgh)
Innovative Technologies in the Molecular Characterization of Pancreatic Cancer
Wei, I. H., & Kumar‐Sinha, C. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6549-2_10
The Role of the Rho GEF Arhgef2 in RAS Tumorigenesis
Cullis, J. E. (2013) · TSpace (University of Toronto)
Genomic Alterations in Sporadic Pancreatic Cancer
Molin, M. D., & Maitra, A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6549-2_1
ZNF300 may influence the metastatic properties in pancreatic ductal adenocarcinoma
Fisher, A. (2014) · Library, Museums and Press - UDSpace (University of Delaware) · doi:10.58088/20w0-a371
Strategies to Target Pancreatic Cancer
Liou, G., & Störz, P. (2016) · Springer eBooks · doi:10.1007/978-3-319-31254-5_1
Cross Talk Between Snail and Mutant K-Ras Contributes to Pancreatic Cancer Progression
Chow, C. R., Ebine, K., Hattaway, H. Z., Kumar, K., & Munshi, H. G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803505-4.00007-2 · Cited by 1
MEK inhibition in pancreas cancer
Vena, F. (2016) · UCL Discovery (University College London)
Oncogenic KRAS and the Inflammatory Micro-Environment in Pancreatic Cancer
Chang, H.-H., Schmidt, A., & Eibl, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803505-4.00005-9
Regulation and Function of the Cancer Stem Cell Transcription Factors GLI1 and Kruppel-like Factor 4
Vanderbilt, D. B. (2015) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.6863
Polireddy, K. (2015) · KU ScholarWorks (The University of Kansas)
Mouse Models of Pancreatic Exocrine Cancer
Pérez-Mancera, P. A. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_77-1
In Vitro Modeling of Pancreatic Duct Cell Carcinogenesis
Leung, L. (2014) · TSpace (University of Toronto)
Elucidating the role of SMAD7 in pancreatic cancer through in vivo studies
Savant, S. S. (2017) · IUScholarWorks (Indiana University) · doi:10.7912/c2/1806
Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials
Patel, M. R., Patel, S. P., & Kurzrock, R. (2017) · Current cancer research · doi:10.1007/978-3-319-63757-0_9
The critical role of cysteine import and metabolism in pancreatic cancer
Badgley, M. A. (2018) · Columbia Academic Commons (Columbia University) · doi:10.7916/d8db8dhx · Cited by 1
The Janus-Faced Role of Cell-Mediated Immune Responses in Pancreatic Cancer
Niccolai, E., Taddei, A., Ricci, F., Ringressi, M. N., & Amedei, A. (2017) · EMJ Oncology · doi:10.33590/emjoncol/10313163
Kopantsev, E. P., Гранкина, Е. В., Kopantseva, M. R., & Sverdlov, E. D. (2017) · Molecular Genetics Microbiology and Virology (Russian) · doi:10.18821/0208-0613-2017-35-3-83-88
Delivery of MicroRNA with CXCR4-Targeted Nanoparticles in Metastatic Cancer Treatment
Xie, Y. (2018) · DigitalCommons@UNMC
Chemo-prevention and interception of obesity-promoted pancreatic ductal adenocarcinoma
Chang, H.-H., & Eibl, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814704-7.00006-4
Regulation of the kRAS Promoter in Pancreatic Cancer by Proteins and Small Molecules
Batra, H. (2017) · ProQuest Demo Repository
Baker, N. M. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/vf3z-jk38 · Cited by 1
Loss of TIP30 Accelerates Pancreatic Cancer Progression and Metastasis
Imasuen, I. (2019) · IUScholarWorks (Indiana University) · doi:10.7912/c2/1902
Immune Selection Pressure Contributes to Pancreatic Cancer Immune EvasionPreprint
Ajina, R., Zuo, A., Wang, S., Moussa, M., Cooper, C. J., Shen, Y. L., Johnson, Q. R., Parks, J. M., Smith, J. C., Catálfamo, M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.15.151274
“Moreover, the pancreatic cancer myelosuppressive microenvironment has been shown to be derived by tumor-intrinsic properties (5,6).”
BackgroundTheoretical and Experimental Tools for Clinical Translation of Quantitative Tissue Optical Sensing.
Lee, S. Y. (2015) · Deep Blue (University of Michigan)
Vieira, G. M. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2021.tde-04082021-130011
Defining Roles of Metabolic Reprogramming in Pancreatic Tumorigenesis and Tumor Maintenance
Nelson, B. S. (2020) · Deep Blue (University of Michigan)
Metadata
- Authors
- Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M.
- Affiliations
- University of Michigan (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2012-02-01
- Volume
- 122
- Issue
- 2
- Pages
- 639-653
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3266788
- OpenAlex
- W2018159884
- Cited by
- 770
- References
- 66
- Citations by year
- 2026: 40 · 2025: 41 · 2024: 53 · 2023: 63 · 2022: 71 · 2021: 80 · 2020: 51 · 2019: 43 · 2018: 54 · 2017: 69 · 2016: 56 · 2015: 45 · 2014: 52 · 2013: 41 · 2012: 11
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Pancreatic Cancer Action Network
- American College of Surgeons
- Vanderbilt University
- University of Pennsylvania
- University of Michigan
- National Institutes of Health (NIH T32, P30 DK, 5-T32-HD007515)
- National Cancer Institute (R01CA151588, P50CA130810, P50CA13810)
- National Institute of General Medical Sciences (T32GM07315, T32GM007315)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034933)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (5-T32-HD007515, T32HD007505)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic cancer, KRAS G12D, oncogenic KRAS, pancreatic carcinogenesis, tumor maintenance, p53, precancerous lesions, epithelial differentiation, Hedgehog signaling, inflammation, tumor microenvironment, tumor regression, KRAS inhibition
- MeSH terms
- Animals, Cell Differentiation, Cell Transformation, Neoplastic, Disease Models, Animal, Epithelial Cells, Humans, Mice, Transgenic, Pancreatic Neoplasms, Pancreatitis, Signal Transduction, Survival Rate, Proto-Oncogene Proteins p21(ras), Mice, Hedgehog Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.